Continuous ketone monitoring for safer sotagliflozin in T1D with CKD
What this study tests
HealthPartners phase 2 trial developing DKA risk mitigation for people with T1D and mild-to-moderate CKD starting SGLT1/2 inhibitor therapy, using continuous glucose and ketone reporting.
Editorial review: .
Registry checked: 2026-09-17. Registry’s own update: 2026-08-27.
Source dates appear in the references where available; this record has no dated citation metadata.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence at a glance
- Who can enter the study?
- Adults 18-75 with T1D and mild-to-moderate chronic kidney disease. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
- Reported benefit and results
- No results posted yet.Read the result sources and their limitations →
- Important harms
- Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
- Research access and approval
- Study regions: United States. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
- What remains uncertain?
- Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.
Research status alone does not establish approval, clinical benefit or local availability.
Primary endpoints
- Change in percentage of time in ketone range >1.5 mmol/L
- Number of diabetic ketoacidosis episodes
The full picture
This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.
Sources
- [1]